Literature DB >> 29473152

White matter spongiosis with vigabatrin therapy for infantile spasms.

Phillip L Pearl1, Annapurna Poduri1,2, Sanjay P Prabhu2,3, Chellamani Harini1, Richard Goldstein2,4, Richard M Atkinson5, Dawna Armstrong6, Hannah Kinney2,7.   

Abstract

The histopathology, "white matter spongiosis," defined by electron microscopy (EM) as "intramyelinic edema," has been associated with vigabatrin therapy in various animal models, but its role or significance in clinical studies is unknown. We conducted a neuropathological examination on a 27-month-old boy with bilateral polymicrogyria and epilepsy after sudden unexpected death in epilepsy (SUDEP). The patient was initiated on vigabatrin at 4 months of age, which controlled infantile spasms, and was continued as maintenance therapy. Autopsy showed a combination of developmental and acquired lesions: (1) bilateral gyral malformations of the frontal, parietal, temporal, and insular cortex; (2) agenesis of the olfactory tracts and bulbs; (3) hippocampal abnormalities: dentate gyrus bilamination and granule cell dispersion; and (4) areas of microscopic bilateral, symmetric white matter spongiosis in the brainstem central tegmental tract, amiculum and hilum of the inferior olive, medial longitudinal fasciculus, paragigantocellularis lateralis, optic nerves and chiasm, and hypothalamus. The white matter spongiosis was identical to the histopathologic lesions (which by EM exhibited intramyelinic edema) that were demonstrated in animal models on vigabatrin therapy, indicating that vigabatrin toxicity is not restricted to animal models. Wiley Periodicals, Inc.
© 2018 International League Against Epilepsy.

Entities:  

Keywords:  GABA transaminase inhibitors; SUDEP/sudden unexpected death in epilepsy; intramyelinic edema; spongiform lesions; vigabatrin toxicity

Mesh:

Substances:

Year:  2018        PMID: 29473152     DOI: 10.1111/epi.14032

Source DB:  PubMed          Journal:  Epilepsia        ISSN: 0013-9580            Impact factor:   5.864


  6 in total

Review 1.  Medical treatment of tuberous sclerosis-related epilepsy.

Authors:  Shimrit Uliel-Sibony; Veronika Chernuha; Hadas Meirson; Aviva Fattal-Valevski
Journal:  Childs Nerv Syst       Date:  2020-08-22       Impact factor: 1.475

2.  Metabolomic analyses of vigabatrin (VGB)-treated mice: GABA-transaminase inhibition significantly alters amino acid profiles in murine neural and non-neural tissues.

Authors:  Dana C Walters; Erland Arning; Teodoro Bottiglieri; Erwin E W Jansen; Gajja S Salomons; Madalyn N Brown; Michelle A Schmidt; Garrett R Ainslie; Jean-Baptiste Roullet; K Michael Gibson
Journal:  Neurochem Int       Date:  2019-02-26       Impact factor: 3.921

Review 3.  Pharmacotherapy for Seizures in Tuberous Sclerosis Complex.

Authors:  Rima Nabbout; Mathieu Kuchenbuch; Catherine Chiron; Paolo Curatolo
Journal:  CNS Drugs       Date:  2021-08-21       Impact factor: 5.749

4.  Transcriptome analysis in mice treated with vigabatrin identifies dysregulation of genes associated with retinal signaling circuitry.

Authors:  Dana Walters; Kara R Vogel; Madalyn Brown; Xutong Shi; Jean-Baptiste Roullet; K Michael Gibson
Journal:  Epilepsy Res       Date:  2020-06-20       Impact factor: 3.045

Review 5.  Modeling epileptic spasms during infancy: Are we heading for the treatment yet?

Authors:  Libor Velíšek; Jana Velíšková
Journal:  Pharmacol Ther       Date:  2020-05-15       Impact factor: 12.310

6.  Preclinical tissue distribution and metabolic correlations of vigabatrin, an antiepileptic drug associated with potential use-limiting visual field defects.

Authors:  Dana C Walters; Erwin E W Jansen; Garrett R Ainslie; Gajja S Salomons; Madalyn N Brown; Michelle A Schmidt; Jean-Baptiste Roullet; K M Gibson
Journal:  Pharmacol Res Perspect       Date:  2019-01-07
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.